Briefing.com uses cookies to store information on your computer that is essential to making the site work and to customizing the user experience. By using the site, you consent to the placement of these cookies. Read our cookie policy to learn more and how to withdraw your consent.     
You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • Google+
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >Lannett: Jerome Stevens puts...
Story Stocks® Archive
Last Update: 20-Aug-18 11:01 ET
Lannett: Jerome Stevens puts the kibosh on distribution agreement; shares fall to 5-year low (LCI)

Shares of Lannett (LCI 5.60, -7.90, -58.5%) lose more than half of their value on a move to worse than five-year lows this afternoon due in part to news that an agreement with family-owned Jerome Stevens Pharmaceuticals, which expires on March 23, 2019, would not be renewed. Additionally, the company gave lower than expected preliminary fourth quarter results.

Lannett released news this morning that JSP had informed the company it would not renew its agreement to distribute three JSP products: Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules USP, Digoxin Tablets USP, and Levothyroxine Sodium Tablets USP upon its expiration in March 2019.

The announcement comes as JSP has already chosen a replacement, Amneal Pharmaceuticals (AMRX 23.54, +2.02, +9.4%). Amneal this morning announced a 10-year license and supply agreement for Levothyroxine sodium tablets with JSP. The agreement is effective March 22, 2019. The agreement includes an upfront milestone payment upon commercialization and a profit share on future sales of Levothyroxine. Further terms of the agreement were not disclosed. AMRX shares cracked 11-month highs today, pushing its two-week advance to 20.5%.

The family has assured Lannett of a continuous supply of the products through March of next year. Lannett noted that these products remain valuable assets for the company and are expected to significantly contribute to its financial performance in fiscal 2019.

Lannett management attempted to quell investor concern about the deal expiration, stating that it was disappointed and intends to redouble its continuing efforts to explore options for addressing its capital structure.

Since the beginning of this year, Lannett notes it has added new products to its offering and expanded its customer base. The company will continue these streamlining efforts. Specifically, Lannett successfully launched eight new products in the first seven months of calendar 2018, which the company estimates will add net sales in excess of $50 mln in fiscal 2019. The company also noted it has completed several transactions to add more than 25 market-ready or near-market-ready product lines to its pipeline.

In addition, in the company’s current fiscal year, it has already submitted four drug applications associated with two product families, implemented a restructuring plan at its Cody Laboratories subsidiary.

In terms of the preliminary results, Lannett expects net sales in the fourth quarter of approximately $171 mln and adjusted EPS between $0.62-0.64. Also, for the fiscal 2018 full year, net sales are expected to be approximately $685 mln, at the low end of the company’s previously provided $685-695 mln range. Also, adjusted EPS attributable to Lannett is expected to be between $3.08-3.10.

In parting, Lannett management offered that its financial performance was within its expected range, with revenue and adjusted net income solidly improved over last year. And, based on the preliminary results, the company highlights that it remains well within its debt financial covenant, and it expect to continue to meet these requirements throughout fiscal 2019.

Lannett will report full financial results for its fiscal 2018 fourth quarter and full year on Tuesday, August 28 after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. ET.

Shares of Lannett (LCI 5.60, -7.90, -58.5%) lose more than half of their value on a move to worse than five-year lows this afternoon due in part to
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Request a Demo
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Cookie Policy
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup